BMC Rheumatology最新文献

{"title":"Circulating exo-miRNA-27a-5p is a novel biomarker of the tofacitinib treatment response in rheumatoid arthritis.","authors":"Jiwei Zhao, Tianjun Zhu, Qiu Liao, Jijia Sun, Fuqun Liu","doi":"10.1186/s41927-025-00502-1","DOIUrl":"https://doi.org/10.1186/s41927-025-00502-1","url":null,"abstract":"<p><strong>Background: </strong>Effective biological markers able to monitor the response of Janus kinase inhibitor (JAKi) are lacking. Exosomal microRNAs (exomiRNAs) can alter their expression during treatment and are ideal biomarkers for therapeutic interventions. In this study, we explored potential biomarkers for monitoring tofacitinib treatment response in patients with RA.</p><p><strong>Methods: </strong>Peripheral blood mononuclear cells (PBMCs) were collected from 35 healthy controls (HCs) and 74 patients with methotrexate (MTX)-resistant new-onset RA. We analyzed the profiles of exomiRNAs using next-generation sequencing (NGS) and verified them using quantitative real-time polymerase chain reaction (qRT-PCR). The functional roles of the selected exomiRNAs were analyzed using bioinformatics tools. Potential exomiRNAs were validated in MTX-resistant RA patients treated with tofacitinib for 3 months.</p><p><strong>Results: </strong>Fifty-six differentially expressed exomiRNAs were identified. High expressions of the exo-(miR-548ah-3p, miR-378 g, miR-27a-5p, and miR-30c-2-3p) were validated by qRT-PCR. Enrichment analysis indicated that these exomiRNAs may regulate immune cells and mediate immune responses. Exo-miR-27a-5p levels significantly decreased after tofacitinib treatment (p < 0.0001) and showed a strong correlation with the DAS28, RF and ESR. Receiver operating characteristic curve analysis showed that changes in the expression levels of exo-miR-27a-5p were significantly correlated with tofacitinib therapy (AUC = 0.92, p < 0.0001).</p><p><strong>Conclusions: </strong>This study suggests that circulating exo-miR-27a-5p is a novel non-invasive biomarker to monitor the response to tofacitinib treatment.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"49"},"PeriodicalIF":2.1,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12036121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social and healthcare professionals' work to establish coherent rehabilitation pathways for people with inflammatory arthritis: a qualitative study.","authors":"Helle Feddersen, Camilla Vestergaard Aarøe, Jens Søndergaard, Lena Andersen, Bettina Munksgaard, Jette Primdahl","doi":"10.1186/s41927-025-00497-9","DOIUrl":"https://doi.org/10.1186/s41927-025-00497-9","url":null,"abstract":"<p><strong>Background: </strong>Professionals in health and social care are challenged by the complexity and fragmentation across primary and secondary levels of care. To study coherent rehabilitation pathways, we focused on people with inflammatory arthritis admitted to a specialised rehabilitation stay as these pathways will involve a myriad of different professionals from primary and secondary levels of care. This study aimed to explore how health and social care professionals establish coherent rehabilitation pathways for people with inflammatory arthritis across primary and secondary levels of care and how organisational factors influence on workflow.</p><p><strong>Methods: </strong>Twenty-four situations between professionals and clients were observed during an inpatient rehabilitation stay. In addition, semi-structured interviews with 26 health and social care professionals from primary and secondary levels of care were conducted. An abductive approach guided the analysis and applied person-centred and integrated care concepts.</p><p><strong>Results: </strong>Three themes were derived from the analysis: (1) Person-centred interactions with clients, highlighting that professionals wanted to respond to clients' preferences; (2) inter-dependent interactions between professionals, reflecting dependence on collaboration across primary and secondary level of care; and (3) economic and cultural frameworks influence professionals' work.</p><p><strong>Conclusion: </strong>Professionals strive to take a person-centred approach and must coordinate and communicate with other professionals to create coherent rehabilitation pathways. However, economic and cultural frameworks influenced by the logic of public management and medical professionalism may hinder these intentions.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"48"},"PeriodicalIF":2.1,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index exhibits an L-shaped association with all-cause mortality in rheumatoid arthritis patients: a retrospective cohort study.","authors":"Jialin Zhang, Yanhua Lin, Jingyan Zeng, Guihu Luo, Pan Liao, Qianyun Chen, Han Zhong, Simei Liang, Cailiu Zhou, Bin Yang, Xing Li","doi":"10.1186/s41927-025-00499-7","DOIUrl":"https://doi.org/10.1186/s41927-025-00499-7","url":null,"abstract":"<p><strong>Background: </strong>The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a novel biomarker reflecting inflammation, nutrition, and immune status, and its potential clinical significance and prognostic role in patients with rheumatoid arthritis (RA) has not been reported.</p><p><strong>Aim: </strong>The objective of this study was to investigate whether CALLY is associated with all-cause mortality in RA patients.</p><p><strong>Methods: </strong>The characteristics of 1101 RA patients and 18,047 non-RA individuals were collected from the National Health and Nutrition Examination Survey (NHANES) database between 1999 and 2010. The CALLY index is calculated as albumin × lymphocyte count / (CRP × 10). Multivariable Cox regression models were used to assess the association between the CALLY index and all-cause mortality in RA patients. Restricted cubic spline (RCS) analysis was applied to evaluate potential linear or nonlinear relationships between the CALLY index and mortality. Kaplan-Meier survival curves were used to assess survival probabilities across different CALLY levels in RA patients.The final analysis was conducted on July 10, 2024.</p><p><strong>Results: </strong>Multivariable logistic regression analysis indicated that a low CALLY index was significantly associated with RA patients when compared to non-RA individuals, with an odds ratio (OR) of 0.74 (95% CI: 0.65-0.83). Cox regression models revealed that RA patients with a higher CALLY index showed a decreased risk of all-cause mortality, with a hazard ratio (HR) of 0.62 (95% CI: 0.51-0.77). RCS analysis demonstrated a L-shaped relationship between the CALLY index and survival outcomes of RA patients. Segmented regression identified an optimal cutoff value for the CALLY index at 12.79, where values below this threshold were inversely correlated with all-cause mortality risk. Subgroup analysis suggested a synergistic interaction between a high Log-CALLY index, male, and age below 60 years. Kaplan-Meier survival curve analysis showed significantly higher survival rates in the high CALLY group compared to the low CALLY group (P = 0.0012).</p><p><strong>Conclusions: </strong>The CALLY index is a valuable biomarker for evaluating the prognosis of patients with RA, and a lower CALLY index indicates an increased long-term mortality risk in RA patients, which suggests the importance of comprehensive assessment for inflammatory status and immune function.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"47"},"PeriodicalIF":2.1,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRI patterns of thigh muscle involvement in immune-mediated necrotizing myopathy and dermatomyositis.","authors":"Anson W Wilks, Kiana M Vakil-Gilani, William D Rooney, Dongseok Choi, Daniela Ghetie, Nizar Chahin","doi":"10.1186/s41927-025-00500-3","DOIUrl":"https://doi.org/10.1186/s41927-025-00500-3","url":null,"abstract":"<p><strong>Background: </strong>Immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) are characterized by weakness, hyperCKemia, associated autoantibodies, and varying extramuscular manifestations. Muscle MRI, currently subordinate to histopathology and serology in idiopathic inflammatory myopathy (IIM) classification, has an evolving role. Our study aims to define thigh muscle MRI involvement in IMNM and DM by direct comparison.</p><p><strong>Methods: </strong>This single-center, retrospective, cross-sectional study included 25 participants, who met IIM classification criteria (14 IMNM, 11 DM) and had available thigh MRI. Clinical and paraclinical data were available and reviewed. 11 muscles were graded for edema on MRI using a semi-quantitative scale (0: normal, 1: <30% of muscle involvement, 2: 31-75%, 3: > 75%). For 3 participants with no significant muscle edema, muscle fatty infiltration was scored according to the same scale. Using linear mixed-effects models, muscle scores were compared between the two groups and a secondary analysis was performed of only edema scores, excluding the 3 participants with fatty infiltration scores.</p><p><strong>Results: </strong>The most affected muscles in IMNM were the semimembranosus (3.0 [2.7-3.0] {median [IQR]}), biceps femoris-long head (BF-LH) (2.7 [2.0-3.0]), and adductors (2.5 [2.0-3.0]). In DM, the most affected muscles were the vastus lateralis (2.7 [2.3-3.0]), vastus intermedius (2.9 [2.2-3.0]), vastus medialis (2.3 [1.7-2.7]), semitendinosus (2.2 [1.0-2.7]), rectus femoris (RF) (2.0 [1.0-2.8]), biceps femoris-short head (BF-SH) (1.9 [1.0-2.7]), gracilis, and sartorius. Intergroup statistical difference of scores was significant (p < 0.01) for 10/11 thigh muscles excluding the RF (p = 0.19), supporting an inverse relationship of muscle involvement for DM and IMNM. The secondary comparative analysis of only muscle edema scores was significant (p < 0.05) for the same 10/11 muscles with a consistent direction for all comparisons.</p><p><strong>Conclusion: </strong>DM and IMNM affect disparate thigh muscles on MRI. DM preferentially affects the anterior thigh, semitendinosus and BF-SH in the posterior thigh, and gracilis in the medial thigh, whereas IMNM preferentially affects the posterior thigh (semimembranosus and BF-LH) and adductors in the medial thigh.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"46"},"PeriodicalIF":2.1,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transitional and CD21^- PD-1⁺ B cells are associated with remission in early rheumatoid arthritis.","authors":"Sarah McGrath, Boel Sundbeck, Katrin Thorarinsdottir, Charlotte A Jonsson, Alessandro Camponeschi, Monica Leu Agelii, Anna-Karin H Ekwall, Merete Lund Hetland, Mikkel Østergaard, Till Uhlig, Michael Nurmohamed, Jon Lampa, Dan Nordström, Kim Hørslev-Petersen, Bjorn Gudbjornsson, Gerdur Gröndal, Ronald van Vollenhoven, Anna Rudin, Inga-Lill Mårtensson, Inger Gjertsson","doi":"10.1186/s41927-025-00487-x","DOIUrl":"https://doi.org/10.1186/s41927-025-00487-x","url":null,"abstract":"<p><strong>Background: </strong>Early initiation of effective treatment is associated with positive long-term prognosis for patients with rheumatoid arthritis (RA). Currently, there are no biomarkers in clinical use to predict treatment response. A predictor of treatment response may be the B-cell compartment, as this is altered in RA patients, making it a potential candidate for predicting treatment response. In this study, we sought to identify B-cell subset(s) at diagnosis that might be associated with Clinical Disease Activity Index (CDAI) remission at 24-week follow-up.</p><p><strong>Methods: </strong>Seventy early RA patients from the NORD-STAR trial, recruited from two Swedish sites, and 28 matched healthy controls, were included in this spin-off study. In NORD-STAR, all patients were randomized to methotrexate (MTX) combined with 1) prednisolone, 2) anti-TNF (certolizumab-pegol), 3) CTLA4-Ig (abatacept), or 4) anti-IL-6R (tocilizumab). Circulating B-cell subsets at diagnosis were assessed by flow cytometry. The primary outcome measure was remission according to CDAI ≤ 2.8. A multivariate two-part discriminant analysis was performed to assess whether B-cell subpopulations at diagnosis could predict remission at 24 weeks. Subsequent univariable statistical analyses were performed using t-tests, Mann-Whitney U, or Kruskal-Wallis tests, as appropriate. Correlations were analyzed using Spearman or Pearson tests, depending on data type. The impact of specific B-cell populations on remission at week 24 was assessed using logistic regression models. The logistic regression model was also used to simultaneously visualize the sensitivity and specificity of the model for all possible values of the exposure (B-cell subpopulations) in predicting the outcome.</p><p><strong>Results: </strong>Patients who achieved CDAI remission at 24 weeks had higher proportions of transitional (p < 0.01) and CD21^- PD-1⁺ (p < 0.01) B cells at diagnosis compared to those who did not. When the two B-cell populations were combined, the sensitivity and specificity for remission, including all treatment arms, were 59% and 86%, respectively. Stratification of the patients by treatment arm revealed a significant negative correlation between the proportion of transitional B cells at baseline and disease activity after 24 weeks of treatment with either MTX and prednisolone or anti-IL-6R.</p><p><strong>Conclusions: </strong>Our results indicate that transitional and CD21^- PD-1⁺ B cells are associated with remission in early RA.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"45"},"PeriodicalIF":2.1,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and factors associated with fatigue in patients with psoriatic arthritis: a systematic review and meta-analysis.","authors":"Haoming Tang, Tricia Li Ting Chew, Warren Fong","doi":"10.1186/s41927-025-00498-8","DOIUrl":"https://doi.org/10.1186/s41927-025-00498-8","url":null,"abstract":"<p><strong>Objectives: </strong>Fatigue is a prominent symptom in patients with psoriatic arthritis (PsA). There was a wide variety of statistics previously reported on fatigue prevalence in patients. This systematic review examined the current literature to derive the overall prevalence of fatigue and risk factors in PsA patients.</p><p><strong>Methods: </strong>A systematic review of the literature with subsequent meta-analyses was conducted. Publications assessing fatigue severity and prevalence in patients with PsA using validated measurement scores were identified from seven online databases (Cochrane, CINAHL, EMBASE, Google Scholar, MEDLINE, PubMed, and Web of Science), from inception until January 2024. Employing a random effects model, we calculated the pooled fatigue prevalence. Quality assessment of included studies was performed utilising the Joanna Briggs Critical Appraisal Tool.</p><p><strong>Results: </strong>The final analysis included 15 studies with 6482 PsA patients. Pooled fatigue prevalence was 0.51 (95% CI: 0.41, 0.61; I2 = 97.4%). There was substantial heterogenicity across the studies, with biologics use and geographical location in terms of Western versus Eastern countries being possible sources of heterogeneity. Age, disease duration, gender, tender joint count, swollen joint and enthesitis count are among the most commonly reported risk factors for fatigue in multivariate logistic regressions.</p><p><strong>Conclusions: </strong>Approximately half of the patients with PsA experienced fatigue. Biologics use and geographical location of the study were possible sources of heterogeneity in the subgroup analysis.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"44"},"PeriodicalIF":2.1,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12007275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of foot function in terms of different pharmacological treatments in a cohort of patients with rheumatoid arthritis: a longitudinal study.","authors":"Maria Gamez-Guijarro, Andres Reinoso-Cobo, Manuel Pardo-Rios, Ana-Belen Ortega-Avila, Laura Ramos-Petersen, Gabriel Gijon-Nogueron, Eva Lopezosa-Reca","doi":"10.1186/s41927-025-00495-x","DOIUrl":"https://doi.org/10.1186/s41927-025-00495-x","url":null,"abstract":"<p><p>This study examines the influence of pharmacological treatments on foot functionality in patients with rheumatoid arthritis over a five-year period. A longitudinal analysis categorized patients into different treatment groups, assessing their foot function using the Foot Function Index (FFI) at the start and end of the study. The groups are based on their pharmacological treatment. Pharmacological treatment groups were categorized into: I methotrexate (MTX), II MTX plus biological treatments (including all variables), III biological treatment alone, and IV a miscellaneous group comprising patients with diverse treatments, including patients for whom various drugs had failed or who had not achieved remission with pharmacological treatment. The study included 206 RA patients with an average age of 58.32 years and a disease evolution of 15.28 years. The analysis of the FFI in total and across its domains of pain, disability, and activity revealed significant differences only in the pain domain (p = 0.011), with a trend toward worsening over time observed in the other domains. Notably, MTX treatment showed improvement in the pain domain (decreasing from 45.76 in 2018 to 40.43 in 2023). Findings suggest that while pharmacological treatments are essential in managing rheumatoid arthritis, their impact on foot function is limited, with MTX demonstrating the most significant benefit in terms of pain reduction.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"43"},"PeriodicalIF":2.1,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IgA vasculitis associated with chronic myelomonocytic leukemia.","authors":"Bénédicte Rouvière, Francois Chasset, Noémie Abisror, Pierre Hirsch, Olivier Fain, Arsène Mékinian","doi":"10.1186/s41927-025-00470-6","DOIUrl":"https://doi.org/10.1186/s41927-025-00470-6","url":null,"abstract":"<p><p>IgA vasculitis is a predominantly pediatric autoimmune disease characterized by IgA deposit in small vessels. Chronic myelomonocytic leukemia (CMML) is a rare hematological malignancy classified within myelodysplastic syndromes. Here, we present a previously unrecognized case of CMML associated with IgA vasculitis. A 62-year-old woman presented with necrotic and infiltrated purpura and mild arthralgia, primarily affecting the knees and wrists, without gastrointestinal or kidney involvement. A comprehensive screening for other etiologies was unremarkable. Blood tests showed an increase of monocyte count and circulating monocyte phenotyping was consistent with CMML. Bone marrow analysis showed no blast cells or karyotypic abnormalities. Genetic testing identified an NRAS mutation. Autoantibody screening and viral serologies were negative. A skin biopsy revealed small-vessel vasculitis with IgA immune deposits. CMML can be associated with autoimmune diseases, such as polyarteritis nodosa and cutaneous leukocytoclastic vasculitis. However, this is the first report of IgA vasculitis occurring in the context of low risk CMML.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"42"},"PeriodicalIF":2.1,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11995566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do infections play a role in the development of chronic inflammatory arthritis? A 14-year follow-up study of patients with early arthritis.","authors":"Riitta Tuompo, Timo Hannu, Leena Paimela, Hannu Kautiainen, Marjatta Leirisalo-Repo, Riitta Koivuniemi","doi":"10.1186/s41927-025-00491-1","DOIUrl":"https://doi.org/10.1186/s41927-025-00491-1","url":null,"abstract":"<p><strong>Background: </strong>The role of preceding infections in the development of reactive arthritis (ReA) is well known but is less studied in association with other inflammatory arthritides. Therefore, in 1979-80 we screened for infections in patients with early musculoskeletal symptoms who were referred for rheumatological consultation and assessed the role of infections and other clinical factors in the development of chronic disease in following 14 years.</p><p><strong>Methods: </strong>A total of 104 consecutive patients with suspected inflammatory musculoskeletal symptoms with a duration < 6 months were examined and screened for preceding infections in an outpatient rheumatology clinic. Follow-up evaluation was conducted after 14 years.</p><p><strong>Results: </strong>ReA, undifferentiated arthritis, and rheumatoid arthritis were the most common diagnoses at baseline and at the 14-year follow-up. Of the 80 patients participating in the 14-year follow-up evaluation, 34 (42.5%) had had evidence of infection at baseline. Twenty-four patients (30%) had developed chronic rheumatic disease. Polyarticular disease at baseline and positive rheumatoid factors predicted the development of chronic diseases. Of the patients originally diagnosed with ReA, 7.3% proceeded to ankylosing spondylitis.</p><p><strong>Conclusion: </strong>At baseline, signs of preceding infections were detected in 41% of the patients with early musculoskeletal symptoms. Preceding infections showed no association with either specific diagnosis of arthritis, except for ReA.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"41"},"PeriodicalIF":2.1,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11987244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Involving young people in research investigating comorbidity associated with childhood-onset rheumatic disease: perspectives of a series of focus groups.","authors":"Sab Siddiq, Jenny Sammy Ainsworth, Clare E Pain, Eve M D Smith, Sizheng Steven Zhao, David M Hughes, Liza J McCann","doi":"10.1186/s41927-025-00492-0","DOIUrl":"https://doi.org/10.1186/s41927-025-00492-0","url":null,"abstract":"<p><strong>Background: </strong>Childhood-onset rheumatic diseases, such as juvenile idiopathic arthritis, juvenile-onset lupus and juvenile dermatomyositis, appear to be associated with an increased risk of comorbidities in adulthood compared to the general population. For the first stage of a research project evaluating this topic, we wanted to capture views from young people with juvenile-onset rheumatic disease to ensure that further work was relevant to their lived experience and priorities. This study aimed to determine (i) which comorbidities young people identify as important, (ii) how they access information about their disease, including comorbidity risk, whether (iii) they would like to hear about the risk of comorbidities whilst they are under paediatric care, and (iv) would be motivated to make lifestyle choices to decrease the risk of potential comorbidities.</p><p><strong>Methods: </strong>A topic guide based on the proposed study aims was developed, and PowerPoint slides were prepared to facilitate three focus group discussions to gain insights from young people. Focus groups were conducted via video platform, and the views of young people were assimilated using notetaking and an online interactive polling tool.</p><p><strong>Results: </strong>A total of 18 young people between 10 and 27 years of age participated in the focus groups. Mental health (including depression and anxiety) was described as important comorbidity by 17/18 (94%), followed by obesity or being overweight by 9/18 (50%), heart disease by 7/18 (39%) and stroke by 5/18 (28%) of participants. Young people reported searching United Kingdom National Health Service websites, charity resources, and Google for information on their disease and associated comorbidities. They stated that they would be willing to change their lifestyle to reduce the risk of comorbidities if information were given to them sensitively with clear practical steps for reducing risk.</p><p><strong>Conclusion: </strong>Three groups of young people identified risk of mental health issues, obesity, and cardiovascular morbidities as particularly important to them. They reported searching online platforms related to their disease and increasingly accessed online resources as they transitioned from paediatric to adult care. Participants thought it would be helpful to provide information on young people's disease and associated comorbidity in a motivational and sensitive way.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"40"},"PeriodicalIF":2.1,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}